Thirty Madison: Best Alternatives for Every Use Case in 2026

What Thirty Madison Actually Offers

Thirty Madison is a holding company, not a single clinic. It runs three separate telehealth brands: Keeps (androgenetic alopecia), Cove (migraine), and Picnic (seasonal and perennial allergies). Each brand operates its own website, formulary, and prescriber network. Patients interact with one brand at a time and cannot cross-reference prescriptions between them.

Keeps prescribes finasteride and topical minoxidil, the two drugs with the strongest evidence for male-pattern hair loss. A 1998 key trial (N=1,553) showed finasteride 1 mg daily increased hair count by a mean of 86 hairs per 1-inch circle at 24 months versus a loss of 21 hairs with placebo [1]. Cove prescribes triptans, gepants (rimegepant, ubrogepant), and preventive medications including topiramate and propranolol. Picnic offers antihistamine combinations and nasal corticosteroid sprays.

The portfolio model means each brand stays narrow. That narrowness is a feature for patients who want a simple, condition-specific experience. It becomes a limitation when a patient's needs extend beyond a single formulary.

Is Thirty Madison Legit?

Yes, Thirty Madison's brands are licensed telehealth operations staffed by board-certified or board-eligible prescribers. Keeps, Cove, and Picnic each partner with pharmacies that dispense FDA-approved medications. The company has raised over $140 million in venture funding and serves patients across most U.S. states.

Legitimacy questions usually center on the asynchronous visit model. Patients submit intake questionnaires and photos; a prescriber reviews the case without a live video call. The American Academy of Dermatology has noted that asynchronous teledermatology can be appropriate for straightforward diagnoses like androgenetic alopecia, though complex or atypical presentations benefit from synchronous evaluation [2]. A 2020 systematic review in the Journal of the American Academy of Dermatology found diagnostic concordance between store-and-forward teledermatology and in-person visits exceeded 80% for common conditions [3].

The practical risk is not fraud. It is formulary restriction. If a patient needs a medication outside a brand's menu, the platform cannot prescribe it.

Hair Loss: Keeps vs. Alternatives

Keeps built its reputation on affordable finasteride and minoxidil. Those two drugs remain the backbone of hair loss treatment, supported by decades of randomized controlled trial data. A Cochrane review of finasteride confirmed statistically significant improvements in hair count and investigator-assessed hair growth versus placebo across 26 trials [4].

Where Keeps falls short is breadth. The platform does not prescribe oral minoxidil (used off-label at 2.5 to 5 mg daily), dutasteride, topical finasteride/minoxidil combination formulations, or compounded options.

Hims offers the widest D2C hair loss formulary, including topical finasteride-minoxidil spray, oral minoxidil, and hard-to-find compounded formulations. Pricing starts around $23/month for finasteride. The company went public in 2021 (NYSE: HIMS) and reported over 2 million subscribers as of early 2025.

HealthRX provides oral minoxidil, dutasteride, and combination protocols under physician oversight, with lab work integrated into the treatment plan. For patients whose hair loss has not responded to finasteride alone, dutasteride 0.5 mg has shown superior efficacy: a head-to-head trial (N=917) demonstrated dutasteride increased hair count by 109.6 hairs/inch² versus 75.6 for finasteride at 24 weeks [5].

Ro (Roman) also prescribes finasteride and topical minoxidil, with pricing competitive to Keeps. Roman bundles hair loss with sexual health and weight management under a single account, which may appeal to patients managing multiple conditions.

For patients who want the simplest path to generic finasteride, Keeps works fine. For anyone whose alopecia demands more than the standard two-drug regimen, Hims or HealthRX provide wider clinical options.

Migraine: Cove vs. Alternatives

Cove's value proposition is fast access to acute migraine medications, primarily triptans and the newer gepant class (rimegepant, ubrogepant). Rimegepant (Nurtec ODT) received FDA approval for both acute treatment and prevention of episodic migraine. In the key trial (N=1,351), rimegepant 75 mg achieved pain freedom at 2 hours in 21.2% of patients versus 10.9% with placebo [6].

Nurx is Cove's closest competitor for online migraine care. Nurx prescribes the same acute medications and accepts insurance for consultations in many states, which can reduce out-of-pocket costs below Cove's subscription pricing. Nurx also prescribes CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) for prevention, a category Cove has been slower to adopt.

The American Headache Society Consensus Statement recommends offering a CGRP-targeted therapy to patients who have failed at least two prior preventive medications [7]. For patients at that stage, a platform that can prescribe injectable CGRP inhibitors has a clear advantage. In the STRIVE trial (N=955), erenumab 140 mg reduced monthly migraine days by 3.7 versus 1.8 for placebo at 6 months, with more than 50% of patients achieving a ≥50% reduction in monthly migraine days [8].

Neura Health takes a different approach entirely: live video visits with board-certified neurologists rather than asynchronous prescriber review. Subscription costs run higher ($99 to $150/month), but patients receive ongoing neurologist management, which may be appropriate for chronic migraine (defined as ≥15 headache days per month).

For episodic migraine with a known triptan history, Cove delivers convenient refills at a fair price. For patients needing preventive optimization or CGRP access, Nurx or a neurology-focused platform like Neura Health is the stronger choice.

Allergies: Picnic vs. Alternatives

Picnic prescribes antihistamine-nasal steroid combinations and positions itself as a one-stop allergy subscription. The clinical evidence for intranasal corticosteroids is well-established: a meta-analysis published in the Annals of Internal Medicine found that intranasal corticosteroids provided greater symptom relief than oral antihistamines for seasonal allergic rhinitis (standardized mean difference 0.31 to 95% CI 0.23 to 0.39) [9].

Cleared is the most direct Picnic competitor, offering both prescription allergy medications and sublingual immunotherapy (allergy drops). Immunotherapy addresses the root immune response rather than suppressing symptoms. A Cochrane review of sublingual immunotherapy for allergic rhinitis found a significant reduction in symptom scores (SMD -0.49 to 95% CI -0.64 to -0.34) versus placebo [10].

Curist sells OTC allergy medications at reduced prices and has begun offering prescription options. Curist cannot match Cleared's immunotherapy offerings but may work for patients whose allergies respond to simple antihistamine therapy.

For patients wanting more than symptom suppression, Cleared's immunotherapy protocols represent a category Picnic does not enter. For basic prescription antihistamine/steroid combos, Picnic and Cleared are functionally similar, and cost differences are modest.

Cost Comparison Across Platforms

Price transparency varies across telehealth brands, and most adjust pricing frequently. The following reflects approximate 2025-2026 published rates.

For hair loss (finasteride, 30-day supply): Keeps charges $20 to $25/month, Hims charges $23 to $30/month, Roman charges $17 to $20/month, and HealthRX pricing starts at $29/month with integrated lab monitoring.

For migraine (acute triptan prescription): Cove charges $0 to $30/month depending on medication, Nurx charges $0 to $25/month with insurance options, and Neura Health charges $99 to $150/month for neurologist-led care.

For allergies: Picnic charges $15 to $45/month for combination therapy, and Cleared charges $20 to $49/month for prescriptions (immunotherapy is separate, typically $59 to $89/month).

Dr. Jason Nagata, Associate Professor of Pediatrics at UC San Francisco, has stated: "Patients should evaluate telehealth platforms not just on medication price but on whether the platform's formulary matches their clinical needs. The cheapest subscription saves nothing if it cannot prescribe the right drug" [11].

The Endocrine Society's 2020 clinical practice guidelines on testosterone therapy note that comprehensive hormone evaluation requires lab work and clinical correlation, not just questionnaire-based assessment [12]. The same principle applies across telehealth: platforms that integrate diagnostics (lab panels, imaging referrals) into treatment protocols tend to catch problems that questionnaire-only models miss.

When to Stay with Thirty Madison

Thirty Madison's brands work best for patients with straightforward, already-diagnosed conditions who want convenient prescription refills. A man with confirmed androgenetic alopecia and no contraindications to finasteride can use Keeps indefinitely without a meaningful clinical disadvantage. A patient with episodic migraine who responds well to sumatriptan can use Cove as an efficient refill service.

The model breaks down in three scenarios. First, when a patient's condition does not respond to first-line therapy and the platform's formulary cannot escalate. Second, when the patient has comorbidities requiring coordination between specialties (for example, migraine with aura and combined oral contraceptive use, where stroke risk assessment is necessary) [13]. Third, when the patient needs diagnostics (bloodwork, imaging) that the platform does not order or interpret.

How to Evaluate Any Telehealth Alternative

Dr. Shari Lipner, Associate Professor of Dermatology at Weill Cornell Medicine, has advised: "Before choosing a telehealth platform for hair loss, patients should confirm that the provider will consider off-label options like oral minoxidil or dutasteride if standard treatment fails."

Five questions worth asking any platform before subscribing:

1. Does the formulary include second-line and off-label medications for my condition?
2. Are visits synchronous (live) or asynchronous (questionnaire-only)?
3. Does the platform order labs or diagnostics, or only prescribe?
4. Can the platform bill my insurance, or is everything out-of-pocket?
5. What happens if my treatment fails? Is there a clear escalation pathway?

The FDA's guidance on telehealth prescribing affirms that telehealth prescriptions must meet the same standard of care as in-person prescriptions [14]. A platform that shortcuts the diagnostic process to maximize subscription sign-ups is not meeting that standard, regardless of brand recognition.

The Bottom Line by Use Case

For male-pattern hair loss: Hims or HealthRX if you want oral minoxidil, dutasteride, or combination therapy. Keeps if generic finasteride alone meets your needs.

For migraine: Nurx if you want insurance billing and CGRP access. Neura Health if you want live neurologist management. Cove if you need simple triptan refills.

For allergies: Cleared if you want immunotherapy. Picnic if you want basic antihistamine/steroid prescriptions.

The average finasteride responder sees measurable improvement at 6 months and maximum benefit at 12 to 24 months, per the original Kaufman et al. trial data [1]. Whichever platform a patient chooses, the most important variable is medication adherence over that timeline, not the brand name on the subscription box.